Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| OCUL - Ocular Therapeutix | 9.18% | Hold | 5,974,800 | $4.95 | $30M | — | — |
| CDXS - Codexis | 8.61% | Hold | 1,345,000 | $20.62 | $28M | — | — |
| Chimerix | 8.40% | Add +5.8% | 5,903,450 | $4.58 | $27M | +323,450 | −$9M |
| HROW - Harrow Health | 6.97% | Add +0.2% | 3,291,343 | $6.82 | $22M | +6,343 | −$6M |
| CRNX - Crinetics Pharmaceuticals | 4.72% | Reduce −4.3% | 693,000 | $21.95 | $15M | −31,400 | −$5M |
| CYTK - Cytokinetics | 4.65% | Reduce −29.9% | 406,500 | $36.81 | $15M | −173,500 | −$11M |
| Keros Therapeutics | 4.49% | Hold | 265,750 | $54.38 | $14M | — | — |
| Protara Therapeutics | 4.24% | Add +0.9% | 2,674,031 | $5.11 | $14M | +24,031 | −$4M |
| Reata Pharmaceuticals · CLASS A | 4.14% | Add +23.3% | 407,002 | $32.76 | $13M | +77,002 | +$5M |
| Kiniksa Pharmaceuticals · CL A | 3.43% | Add +8.5% | 1,112,500 | $9.94 | $11M | +87,500 | −$1M |
| ETON - Eton Pharmaceuticals | 3.22% | Reduce −0.2% | 2,379,275 | $4.36 | $10M | −5,725 | +$142K |
| Merus | 2.78% | Add +6.4% | 338,000 | $26.44 | $9M | +20,200 | −$1M |
| STXS - Stereotaxis | 2.78% | Reduce −5.2% | 2,395,600 | $3.73 | $9M | −130,900 | −$7M |
| Tracon Pharmaceuticals | 2.58% | Add +3.3% | 3,155,098 | $2.63 | $8M | +100,098 | −$164K |
| BCYC - Bicycle Therapeutics | 2.38% | New | 175,000 | $43.88 | $8M | +175,000 | +$8M |
| XOMA - XOMA Del | 2.35% | Reduce −19.9% | 271,000 | $27.98 | $8M | −67,350 | +$528K |
| CLDX — | 2.07% | Reduce −76.8% | 195,500 | $34.06 | $7M | −648,500 | −$26M |
| PTGX - Protagonist Therapeutics | 1.85% | Reduce −26.5% | 251,500 | $23.68 | $6M | −90,500 | −$6M |
| TELA - Tela Bio | 1.72% | Add +6.0% | 477,000 | $11.63 | $6M | +27,133 | −$210K |
| Fortress Biotech | 1.58% | Hold | 3,750,000 | $1.36 | $5M | — | — |
| PCVX - Vaxcyte | 1.58% | Reduce −33.2% | 211,000 | $24.15 | $5M | −104,800 | −$2M |
| FDMT - 4D Molecular Therapeutics | 1.53% | Add +41.9% | 325,000 | $15.12 | $5M | +96,000 | −$110K |
| LRMR - Larimar Therapeutics | 1.19% | Add +6.8% | 943,702 | $4.05 | $4M | +60,100 | −$6M |
| Ginkgo Bioworks · CLASS A | 1.16% | Hold | 929,780 | $4.03 | $4M | — | — |
| Semler Scientific | 1.08% | Reduce −59.3% | 70,000 | $49.56 | $3M | −102,000 | −$12M |
| Macrogenics | 1.03% | Reduce −18.5% | 376,400 | $8.81 | $3M | −85,600 | −$4M |
| Verastem | 1.02% | Hold | 2,325,000 | $1.41 | $3M | — | — |
| FULC - Fulcrum Therapeutics | 1.00% | New | 136,000 | $23.65 | $3M | +136,000 | +$3M |
| MASS - 908 Devices | 0.98% | New | 166,406 | $19.01 | $3M | +166,406 | +$3M |
| EWTX - Edgewise Therapeutics | 0.91% | New | 303,000 | $9.70 | $3M | +303,000 | +$3M |
| Mersana Therapeutics | 0.88% | New | 710,000 | $3.99 | $3M | +710,000 | +$3M |
| Hyperfine · CL A | 0.84% | Hold | 763,075 | $3.54 | $3M | — | — |
| Synlogic | 0.73% | Add +15.8% | 984,200 | $2.40 | $2M | +134,200 | +$305K |
| PRQR - Proqr Therapeutics | 0.68% | Add +68.9% | 2,425,000 | $0.9052 | $2M | +989,490 | −$9M |
| Neoleukin Therapeutics | 0.46% | Reduce −24.6% | 790,000 | $1.88 | $1M | −257,300 | −$4M |
| Aveo Pharmaceuticals | 0.42% | Reduce −8.9% | 240,000 | $5.59 | $1M | −23,400 | +$107K |
| Graphite Bio | 0.40% | New | 255,500 | $5.10 | $1M | +255,500 | +$1M |
| LQDA - Liquidia | 0.40% | Add +964.3% | 178,800 | $7.18 | $1M | +162,000 | +$1M |
| Modular Medical | 0.36% | New | 266,100 | $4.40 | $1M | +266,100 | +$1M |
| Avalo Therapeutics | 0.33% | Reduce −0.3% | 1,454,400 | $0.7247 | $1M | −5,000 | −$1M |
| Nucana | 0.27% | Reduce −26.1% | 878,700 | $0.9992 | $878K | −310,300 | −$2M |
| Repare Therapeutics | 0.25% | New | 55,678 | $14.24 | $793K | +55,678 | +$793K |
| Sutro Biopharma | 0.23% | Reduce −86.8% | 89,980 | $8.22 | $740K | −590,020 | −$9M |
| DERM - Journey Medicine | 0.10% | New | 67,000 | $4.84 | $324K | +67,000 | +$324K |
| Biolinerx | 0.01% | Hold | 16,667 | $1.74 | $29K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| BBIO - Bridgebio Pharma | 1.16% | Exit | 0 | $16.68 | $5M | −328,100 | −$5M |
| Sierra Oncology | 0.76% | Exit | 0 | $21.74 | $4M | −165,778 | −$4M |
| Mei Pharma | 0.74% | Exit | 0 | $2.67 | $4M | −1,315,000 | −$4M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2